BrainsWay - Public Comps and Valuation Multiples

BrainsWay Overview

About BrainsWay

BrainsWay Ltd is engaged in advanced noninvasive neurostimulation treatments for mental health disorders. The company is advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. Current indications include depressive disorder (including reduction of anxiety symptoms, commonly referred to as anxious depression), obsessive-compulsive disorder and smoking addiction. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. The company derives revenues from the lease and sale of Deep TMS systems.

Founded

2006

HQ

Employees

106

Website

brainsway.com

Sectors

Medical Devices
DeepTech
HealthTech

Financials

LTM Revenue n/a

LTM EBITDA n/a

EV

$117M

Valuation Multiples

Multiples.vc

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

BrainsWay Financials

BrainsWay has a last 12-month revenue of n/a and a last 12-month EBITDA of n/a.

In the most recent fiscal year, BrainsWay achieved revenue of $8.6M and an EBITDA of -$0.7M.

BrainsWay expects next 12-month revenue of XXX and NTM EBITDA of XXX

See BrainsWay valuation multiples based on analyst estimates

BrainsWay P&L

	FY 2023	FY 2024	FY 2025	LTM	NTM
Revenue	$7.4M	$8.6M	XXX	XXX	XXX
Gross Profit	$6.3M	$5.4M	XXX	XXX	XXX
Gross Margin	85%	63%	XXX	XXX	XXX
EBITDA	-$3.1M	-$0.7M	XXX	XXX	XXX
EBITDA Margin	-42%	-8%	XXX	XXX	XXX
Net Profit	-$1.8M	-$3.6M	XXX	XXX	XXX
Net Margin	-24%	-42%	XXX	XXX	XXX
Net Debt	n/a	n/a	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

BrainsWay Stock Performance

As of April 15, 2025, BrainsWay's stock price is ILS 16 (or $4).

BrainsWay has current market cap of ILS 600M (or $163M), and EV of ILS 431M (or $117M).

See BrainsWay trading valuation data

BrainsWay Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$117M	$163M	XXX	XXX	XXX	XXX	n/a

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

BrainsWay Valuation Multiples

As of April 15, 2025, BrainsWay has market cap of $163M and EV of $117M.

BrainsWay's trades at n/a LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate BrainsWay's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See valuation multiples for BrainsWay and 10K+ public comps

BrainsWay Financial Valuation Multiples

	FY 2024	FY 2025E	FY 2026E	FY 2027E
EV	$117M	XXX	XXX	XXX
EV/Revenue	13.5x	XXX	XXX	XXX
EV/EBITDA	-168.2x	XXX	XXX	XXX
P/E	-143.0x	XXX	XXX	XXX
P/E/Growth	n/a	XXX	XXX	XXX
EV/FCF	-390.4x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get BrainsWay Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

BrainsWay Valuation Multiples

BrainsWay's NTM/LTM revenue growth is n/a

BrainsWay's revenue per employee for the last fiscal year averaged $0.1M, while opex per employee averaged $0.1M for the same period.

Over next 12 months, BrainsWay's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .

Analysts estimate BrainsWay's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See operational valuation multiples for BrainsWay and other 10K+ public comps

BrainsWay Operational Valuation Multiples

	FY 2024	NTM	FY 2025E	FY 2026E	FY 2027E
Revenue Growth	17%	XXX	XXX	XXX	XXX
EBITDA Margin	-8%	XXX	XXX	XXX	XXX
EBITDA Growth	-78%	XXX	XXX	XXX	XXX
Rule of 40 (SaaS-only)	n/a	XXX	XXX	XXX	XXX
Revenue per Employee	$0.1M	XXX	XXX	XXX	XXX
Opex per Employee	$0.1M	XXX	XXX	XXX	XXX
S&M Expenses to Revenue	19%	XXX	XXX	XXX	XXX
G&A Expenses to Revenue	49%	XXX	XXX	XXX	XXX
R&D Expenses to Revenue	21%	XXX	XXX	XXX	XXX
Opex to Revenue	89%	XXX	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry